Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.74 |
| ▸ | MAPT | P10636 | 4/20 | 0.74 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.74 |
| ▸ | TP53 | P04637 | 3/20 | 0.74 |
| ▸ | TSHR | P16473 | 3/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.74 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.74 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.74 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.74 |
| ▸ | THPO | P40225 | 1/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.74 |
| ▸ | RECQL | P46063 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.61 |
| ▸ | HRH1 | P35367 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8593280 | 1.00 | MEN1 (0.74) | MEN1KMT2AMAPTSLC25A20TP53 | |
| SCHEMBL14931520 | 0.95 | MEN1 (0.76) | MEN1KMT2AMAPTSLC25A20TP53 | |
| SCHEMBL997303 | 0.94 | MEN1 (0.79) | MEN1KMT2AMAPTSLC25A20TP53 | |
| SCHEMBL28525260 | 0.94 | MEN1 (0.79) | MEN1KMT2AMAPTSLC25A20TP53 | |
| SCHEMBL11973504 | 0.94 | MEN1 (0.79) | MEN1KMT2AMAPTSLC25A20TP53 | |
| SCHEMBL15050371 | 0.94 | MEN1 (0.79) | MEN1KMT2AMAPTSLC25A20TP53 | |
| SCHEMBL995307 | 0.94 | MEN1 (0.79) | MEN1KMT2AMAPTSLC25A20TP53 | |
| Hydrochloric Acid SCHEMBL28705824 | 0.93 | MEN1 (0.77) | MEN1KMT2AMAPTSLC25A20TP53 | |
| SCHEMBL2351087 | 0.92 | MEN1 (0.80) | MEN1KMT2AMAPTSLC25A20TP53 | |
| SCHEMBL17891477 | 0.92 | MEN1 (0.85) | MEN1KMT2AMAPTSLC25A20TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240398845-A1 | USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF CARDIAC DISEASES IN NON-HUMAN MAMMALS EXCLUDING FELINES, IN PARTICULAR CANINES | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2024-12-05 | — | — | US | claimed |
| US-20240390332-A1 | Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more SGLT-2 inhibitors and telmisartan | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2024-11-28 | — | — | US | claimed |
| US-20240307426-A1 | USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF RENAL DISEASES IN NON-HUMAN MAMMALS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2024-09-19 | — | — | US | claimed |
| CN-118615450-A | Use of SGLT-2 inhibitors for the prevention and/or treatment of heart diseases in felines | 勃林格殷格翰动物保健有限公司 | 2024-09-10 | — | — | CN | claimed |
| CN-115087441-B | Use of SGLT-2 inhibitors for the prevention and/or treatment of heart diseases in felines | 勃林格殷格翰动物保健有限公司 | 2024-07-12 | — | — | CN | claimed |
| EP-4376830-A1 | USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF RENAL DISEASES IN NON-HUMAN MAMMALS | Boehringer Ingelheim Vetmedica GmbH (DE) | 2024-06-05 | — | — | EP | claimed |
| US-20240094216-A1 | ODD CHAIN FATTY ACID THERAPY FOR THE TREATMENT OF MITOCHONDRIAL DISEASES | UNIVERSITY OF SOUTH CAROLINA | 2024-03-21 | — | — | US | claimed |
| CN-117715640-A | Use of SGLT-2 inhibitors for preventing and/or treating heart diseases in non-human mammals excluding felines, particularly canines | 勃林格殷格翰动物保健有限公司 | 2024-03-15 | — | — | CN | claimed |
| CN-117715639-A | Use of SGLT-2 inhibitors for the prevention and/or treatment of kidney disease in non-human mammals | 勃林格殷格翰动物保健有限公司 | 2024-03-15 | — | — | CN | claimed |
| US-20240050456-A1 | USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREAT-MENT OF CARDIAC DISEASES IN FELINES | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2024-02-15 | — | — | US | claimed |
| US-20030022937-A1 | Therapy of neuro-degenerative disorder by administering D-beta - hydroxybutyric acid, acetoacetate, or a metabolic precursor or physiologically acceptable salt of D- beta -hydroxybutyric acid or acetoacetate | BTG INTERNATIONAL LIMITED | 2003-01-30 | — | — | US | claimed |
| US-6323237-B1 | NEURODEGENERATIVE DISORDER, MEMORY LOSS WITH AGING, INABILITY TO METABOLIZE GLUCOSE AND ENZYME INHIBITORS FOR PYRUVATE DEHYDROGENASE | BTG INTERNATIONAL LIMITED (GB) | 2001-11-27 | — | — | US | claimed |
| US-20010041736-A1 | Therapy for nervous system disorders | BTG INTERNATIONAL LIMITED | 2001-11-15 | — | — | US | claimed |
| EP-1098630-A2 | COMPOSITION FOR ENHANCING EPIDERMAL LIPID PRODUCTION | Biomed Research and Technologies, Inc. (US) | 2001-05-16 | — | — | EP | claimed |
| WO-2000004870-A2 | COMPOSITION FOR ENHANCING EPIDERMAL LIPID PRODUCTION | BIOMED RESEARCH AND TECHNOLOGIES, INC. (US) | 2000-02-03 | — | — | WO | claimed |
| EP-0514357-B1 | Use of esters of acyl L-carnitines with gamma-hydroxybutyric acid for producing pharmaceutical compositions for the treatment of hepatopathies | SIGMA TAU IND FARMACEUTI (IT) | 1996-01-10 | — | — | EP | claimed |
| US-5246967-A | USE OF ESTERS OF ACYL L-CARNITINES WITH GAMMA-HYDROXYBUTYRIC ACID FOR PRODUCING PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATOPATHIES | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1993-09-21 | — | — | US | claimed |
| EP-0514357-A1 | Use of esters of acyl L-carnitines with gamma-hydroxybutyric acid for producing pharmaceutical compositions for the treatment of hepatopathies | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1992-11-19 | — | — | EP | claimed |
| US-4415589-A | Use of carnitine and of lower acyl-carnitines in the therapeutic treatment of the pathology of the veins | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1983-11-15 | — | — | US | claimed |
| US-4194006-A | ANTIARRHYTHMIA | CAVAZZA CLAUDIO (IT) | 1980-03-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240050456-A1 | USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREAT-MENT OF CARDIAC DISEASES IN FELINES | SLC5A2, SLC5A1, SLC16A1 | MEN1 3162/4885KMT2A 888/4885MAPT 473/4885 |
| US-20240307426-A1 | USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF RENAL DISEASES IN NON-HUMAN MAMMALS | SLC5A2, SLC5A1, SLC2A1 | MEN1 2349/4885KMT2A 2171/4885MAPT 1097/4885 |
| US-20240094216-A1 | ODD CHAIN FATTY ACID THERAPY FOR THE TREATMENT OF MITOCHONDRIAL DISEASES | NDUFAB1, OAT, CPT2 | MEN1 3476/4885KMT2A 2356/4885MAPT 1246/4885 |
| US-20240398845-A1 | USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF CARDIAC DISEASES IN NON-HUMAN MAMMALS EXCLUDING FELINES, IN PARTICULAR CANINES | SLC5A2, SLC5A1, SLC2A1 | MEN1 2290/4885KMT2A 1401/4885MAPT 1360/4885 |
| US-20010041736-A1 | Therapy for nervous system disorders | GYS1, CPT1B, PYGB | MEN1 2300/4885KMT2A 2187/4885MAPT 116/4885 |
| US-20030022937-A1 | Therapy of neuro-degenerative disorder by administering D-beta - hydroxybutyric acid, acetoacetate, or a metabolic precursor or physiologically acceptable salt of D- beta -hydroxybutyric acid or acetoacetate | CPT1B, BDNF, IAPP | MEN1 1712/4885KMT2A 2503/4885MAPT 352/4885 |
| US-20240390332-A1 | Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more SGLT-2 inhibitors and telmisartan | SLC5A2, SLC5A1, REN | MEN1 660/4885KMT2A 1245/4885MAPT 895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.